Clinical Trial Search

Primary: 24hr Urine Measurements of the Effect of SGLT-2 Inhibitor Therapy on Cystine Production in Urine in Patients With Cystinuria — 999.3 24hr urine cystine concentration…

Primary: Change in Cystine Capacity From Baseline — -63.6; 76; 53.4; 103.1 mg/L

Primary: Cystine Capacity — 43.1 mg/L

Primary: Plasma Pharmacokinetic Parameter: Cmax of Cysteamine — 42.02; 33.06 umol/L

Primary: The Steady-state White Blood Cell Cystine Levels of RP103 Compared to Cystagon® — 0.5152; 0.4367 nmol ½ Cystine / mg protein — p=0.0001

Primary: Urinary Cystine Supersaturation (mg/L) at High Dose (Day7-8) — 70 mg/L

Primary: Number of Participants With Serious and Non-Serious Adverse Events — 257 participants

Primary: Number of Participants With Treatment-emergent Adverse Events — 58; 37; 24; 32 Participants

Primary: Cystine Stone Recurrence — 16; 23 Participants

Primary: Average Difference Between Morning and Non-Morning Log White Blood Cell (WBC) Cystine Values — -0.229; 0.080 log [nmol ½ cystine/mg protein] — p=0.0048

Primary: Difference in Thiobarbituric Acid Reactive Substances (TBARS) in Individuals With Cystathionine Beta Synthase Deficient Homocystinuria (CBSDH) Pre and Post Taurine…

Primary: 24 Hour Urine Supersaturation of Calcium Oxalate (CaOx) — 1.83; 1.83; 1.87; 1.78 KJoules/mol — p=0.32

Primary: Mean White Blood Cell (WBC) Cystine Concentration at Each Visit — 3.1709; 2.2899; 1.8474; 2.3403 nmol 1/2 Cystine/mg protein

Primary: Cysteamine Absorption: Area Under the Plasma Concentration Curve (AUC) — 3618; 2799; 2457 min*uM — p=.04

Primary: Number of Participants Who Had Positive Genetic Test Results — 4 Participants

Primary: Urinary Calcium Phosphate Saturation — 2.38; 1.97; 2.19 no units

Primary: Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) — 25; 18 participants — p=0.34

Primary: Clinical Cure — 140; 123; 10; 27 participants

Primary: To Evaluate the Effect of Oral Supplementation With Lactobacillus Reuteri on the Frequency of Confirmed UTI in Adult Women With Recurrent UTI. — 1.2; 1.3 Number of…

Primary: Measures of Liver Function: AST and ALT — 36.2; 52; 31.7; 57.86 IU/L

Primary: Change From Baseline Period to Treatment Period 24-hour Urinary Oxalate Excretion — -13.92 mg/day

Primary: The Plasma and Urine Parameters — 6800; 6800; 3700; 3700 mg per dL

Primary: Percentage of Predicted Function (Percent-Predicted) of Forced Expiratory Volume in One Second (FEV1) at Baseline — 62.092; 60.232 percentage of predicted FEV1 — p=0.3264

Primary: Change in Cellular Granular Osmiophilic Deposits (GRODs) in Electron Micrographs of Peripheral White Blood Cells. — -0.3317 Average number of GRODs

Primary: Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population) — 48; 42; 46; 7 Participants

Primary: Change in Urine cAMP Concentration and Urine Osmolality (UOsm) — -2.6; -2.0 fold change in cAMP/UOsm (umol/UOsm)

Primary: Percent of Oxalate Absorption Normalized by Baseline Urinary Oxalate Excretion Over a 24 Hour Test Period — 2.84 percentage of oxalate absorption

Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 100; 97.9; 14.7; 18.8 percent of participants

Primary: Change in Urine Total Protein — 1681; 59 mg/day

Primary: Concentration of Glutamine and Myoinositol by MRS — 4.97; 3.66; 3.78; 4.50 mM — p=0.003